You are here: Industry Insights > cambrex

News List

Cambrex completes GMP manufacturing expansion in Estonia firstwordpharma
May 31, 2021
The expansion will accelerate the progression and tech transfer of projects within the early clinical development phases
Cambrex Adds Kilogram-Scale Mfg. Capabilities at Estonia contractpharma
May 27, 2021
Cambrex completed an investment project at its facility in Tallinn, Estonia to upgrade its kilogram-scale lab for the manufacture of pharmaceutical intermediates under current good manufacturing practice (CGMP) conditions.
Cambrex Expands Analytical Services Capabilities contractpharma
May 12, 2021
Cambrex has expanded its cGMP analytical testing capabilities at its site in Longmont, CO. Existing space at the site has been repurposed with cutting edge technologies and doubles the footprint of the laboratory operations.
Cambrex Expands API Mfg. Capacity in Charles City contractpharma
November 18, 2020
Cambrex is expanding its mid-scale and large-scale API manufacturing capacity in Charles City, Iowa. The $50+ million investment aims to meet growing demand for small molecule drug substance development and manufacturing.
Cambrex Completes Edinburgh Expansion contractpharma
October 14, 2020
Doubles the facility's footprint to 15,000 sq.-ft., existing lab space is refurbished, and an additional 3,500 sq.-ft. of lab space added.
Cambrex Names Thomas Loewald as CEO contractpharma
June 19, 2020
Fifteen-year vet of Thermo Fisher, currently president of ProAmpac.
Cambrex Completes Biopharma Expansion contractpharma
April 08, 2020
The Durham, NC site now features a range of new instruments, including particle analysis and imaging.
Cambrex Appoints Troy Player as President, Early Stage Development & Testing Business Unit Cambrex
April 01, 2020
Cambrex announced that Troy Player has been appointed as President, Early Stage Development and Testing (ESDT).
Cambrex Appoints Early Stage Development & Testing BU President contractpharma
April 01, 2020
Troy Player brings more than 25 years of experience in senior strategic and operational executive roles.
Permira affiliate to buy small molecule company Cambrex for $2.4bn pharmaceutical-technology
August 08, 2019
An affiliate of private equity firm Permira Funds is set to acquire small molecule company Cambrex in a deal valued at approximately $2.4bn.

Previous page 1 2 Next page